Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I very sadly said goodbye to my beloved Mustang this morning at a slight profit in order to buy another stock whose price had just become too attractive and has disruptive prospects in its industry (NVTA). This is still a very promising company and I may yet return when I have more investment capital, but for now I had to leave. I think any buyer will be pleased in the long run if they buy Mustang at this price.
And still the price keeps steadily advancing. What a shame so few investors are paying attention.
The stock price just keeps on advancing. This quality company is one of the best small biopharmas around, yet very few investors seem to be aware of its existence.
This has just capped off a great week. In the long run this will trade much higher than what it is trading at now.
Good news and a nice increase today. This well-managed company has really good long-term potential.
That's because people are afraid of the potential dilution from the $100 million stock filing. All I can say is that if Manny Lichtman was willing to pay $3.25 for this back in the spring, I have confidence in buying anywhere below that, and I believe they have a pipeline that will prove to be worth far more than where it is trading now in a couple of years.
I don’t get it, they getting all high buy ratings from everywhere. Everytime good news comes out it sells off
MBIO $10 TARGET PRICE TODAY WOOHOOOOOOOOOO
This keeps moving up slowly but surely - I think this has some of the best long-term prospects in small cap biopharma.
They'll need to sell more shares as time goes on, but that's because they have significant needs to fund all the areas of the business that have great potential. I think these people know what they're doing, and they have heavyweight backing. I think the stock price will be much higher in five years than where it is now, and I'm willing to hold long to see how they will develop the business.
* * $MBIO Video Chart 05-26-2020 * *
Link to Video - click here to watch the technical chart video
* * $MBIO Video Chart 04-30-2019 * *
Link to Video - click here to watch the technical chart video
Lol I never seen it spread out like that.
* * $MBIO Video Chart 04-22-2019 * *
Link to Video - click here to watch the technical chart video
This has been all over the news this past week. It will be interesting to see how the stock price reacts this week. Appears this is a cure for bubble boy disease. The question remains is how many suffer from this disease and what is the potential revenue moving forward?
* * $MBIO Video Chart 04-18-2019 * *
Link to Video - click here to watch the technical chart video
One analyst and he’s been know to drink a few while making these predictions. He 50/50 at best
I agree, it'll head lower. There like won't be significant news till end of the year. 2020 will be a good year, 2121 will be excellent should it continue the progress
Price target by the analysts:
$18
Today it can close around.
This is holding gains nicely now. Going to close higher. $16s were hitting last night in AH LOL
Don’t think so......4’s may be in the distant future. Opportunity to avg down
Hope so in @6.50
ur welcome
Thanks...
crude
i tried i dont know how to get it
mark breidenbach from oppenheimer
Mustang Bio Inc (NASDAQ: MBIO) announced the publication in the New England Journal of Medicine, of data from a Phase 1/2 trial conducted by St. Jude Children's Research Hospital that is evaluating lentiviral gene therapy for treating newly-diagnosed infants under two years old with XSCID, or SCID-X1, aka bubble boy disease. Mustang Bio has licensed the lentiviral gene therapy for commercial use, and has named it MB-107.
The data showed that the therapy was well tolerated, and seven of the eight treated patients showed normalization of CD3+, CD4+ and CD4+ naïve T-cell and natural killer cell numbers within three to four months after treatment.
"The results have been very good thus far. We've been able to restore a full immune system pretty quickly," the company said.
What analyst? Post a link
not mine a new analyst covering the stock today gives it a $18 PT
Followers
|
18
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
177
|
Created
|
08/24/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |